REG - Creo Medical Group - Secretary of State for Wales site visit

Creo MedicalAnnouncement

13/07/2020 10:10

RNS Number : 8076S
  
Creo Medical Group PLC
  
13 July 2020
  
 

Creo Medical Group plc
("Creo" or the "Company")
 
Secretary of State for Wales site visit 
Simon Hunt MP shown plans for using Cool Plasma technology to combat COVID-19
 
Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of surgical endoscopy, announces that it hosted a visit from the Secretary of State for Wales, Simon Hunt MP, at its Chepstow Head Office on Friday 10 July 2020.
 
As well as showing the Welsh Secretary shown Creo's range of advanced energy surgical endoscopy products, the Company also gave a presentation on its Cool Plasma technology. Creo's Cool Plasma technology has a proven, high efficacy kill of bacteria, and is expected to be highly effective in the inactivation of viruses.  6 log (i.e. 99.9999%) kill has been shown on the most resilient bacteria, including MRSA. E.Coli, K.Pneumoniae and C. difficile. Initial research and third-party testing indicates a consistent view that Creo's Cool Plasma would inactivate (kill) the SARS-CoV-2 virus given its performance on relatively 'tougher' bacteria. 
 
The presentation contained a video of the Cool Plasma technology and is available to view here:
https://www.creomedical.com/2020/07/08/development-loan-for-plasma-sterilising-product/
 
On 2 July, the Company announced that it had secured a £2m loan from the Cardiff Capital Region to develop Creo's Cool Plasma technology as a method to kill bacteria and viruses and for sterilisation purposes. The five-year loan will ultimately support the creation of Creo's Plasma Division which will focus on the use of Creo's CROMA Advanced Energy platform to create safe environments through sterilisation and decontamination.
 
Secretary of State for Wales, Simon Hart said:
"It is fantastic to see Welsh companies stepping up to the challenges created by this pandemic and developing technology that can make a real difference in the fight against Covid-19.
 
"The Cardiff Capital Region's £2 million investment will boost the innovative research that is already taking place at Creo Medical and help to cement South Wales' position as a world leader in the development of medical technology."
 
Craig Gulliford, Chief Executive Officer of Creo, said:
"We were very pleased to welcome the Secretary of State for Wales to our facilities here in Chepstow. We are proud to have taken our expertise in developing innovative medical devices and applied them to our plasma technology to develop products that could help halt the spread of Coronavirus. Wales has a strong reputation for producing technology rich and innovative life sciences companies and I am delighted we have established a platform to develop critical medical tools here in the UK that will benefit cancer patients worldwide, and to protect our nation against a resurgence of COVID-19."
 
 
Enquiries:
 



Creo Medical Group plc


investors.creomedical.com




Richard Rees (CFO)


+44 (0)1291 606 005




 


 




Cenkos Securities plc


+44 (0)20 7397 8900




Stephen Keys / Cameron MacRitchie (NOMAD)


 




Michael Johnson / Russell Kerr (Sales)


 




 


 




Walbrook PR Ltd


Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com




Paul McManus / Lianne Cawthorne 


Mob: +44 (0)7980 541 893 / +44 (0)7515 909 238 



 
About Creo Medical 
 
Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy.  The Company's mission is to improve patient outcomes by applying microwave and RF energy to surgical endoscopy.  Creo has developed CROMA, an electrosurgical Advanced Energy Platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation.  This technology provides clinicians with flexible, accurate and controlled surgical solutions. 
 
The Company's strategy is to bring its CROMA Advanced Energy Platform powered by unique full spectrum adaptive technology to market enabling a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs.  The CROMA Advanced Energy platform will be developed further for bronchoscopy and laparoscopy procedures.  The Company believes its technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option of treatment. 
 
For more information about Creo Medical please see our website, investors.creomedical.com 
 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
MSCGPUCUMUPUUBW